MyFinsight
Home
Blog
About
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$24,060K
Free Cash flow
$12,282K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Accounts receivable
Proceeds from exercise of common...
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Net loss
Deferred revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-21,972
-24,361
-31,946
-24,313
Depreciation
463
469
468
501
Stock-based compensation
9,062
9,269
9,515
9,044
Accretion of discounts on investments, net
2,886
2,624
3,524
4,623
Accounts receivable
-34,851
35,000
-
-
Prepaid expenses and other current assets
1,612
1,343
227
-449
Other long-term assets
-1,031
1,336
-19
-66
Accounts payable
-342
-1,612
1,669
-168
Accrued expenses
4,045
-2,030
-4,516
6,179
Deferred revenue
-10,118
46,267
0
0
Operating lease right-of-use assets and liabilities, net
38
36
0
-9
Net cash provided by (used in) operating activities
12,484
-12,337
-28,542
-12,856
Purchases of property and equipment
202
273
106
93
Purchases of short-term investments
144,842
112,751
123,277
117,969
Maturities of short-term investments
106,260
121,310
152,926
126,368
Net cash used in investing activities
-38,784
8,286
29,543
8,306
Proceeds from exercise of common stock options and employee stock purchase plan
5,785
-
2,944
493
Proceeds from exercise of common stock options
-
3,545
-
-
Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs
-
-
0
0
Payments of issuance costs
0
0
-
-
Net cash provided by financing activities
2,240
3,545
2,944
493
Net decrease in cash, cash equivalents and restricted cash
-24,060
-506
3,945
-4,057
Cash, cash equivalents and restricted cash - beginning of year
52,644
53,150
49,205
431,421
Cash, cash equivalents and restricted cash - end of period
28,584
52,644
53,150
49,205
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Accounts receivable
-$34,851K
Proceeds from exercise of
common stock options...
$5,785K
(211.86%↑ Y/Y)
Stock-based compensation
$9,062K
(-58.17%↓ Y/Y)
Accrued expenses
$4,045K
(-12.58%↓ Y/Y)
Other long-term
assets
-$1,031K
(-439.79%↓ Y/Y)
Depreciation
$463K
(-56.32%↓ Y/Y)
Net cash provided by
(used in) operating...
$12,484K
(130.57%↑ Y/Y)
Net cash provided by
financing activities
$2,240K
(48.54%↑ Y/Y)
Canceled cashflow
$36,968K
Canceled cashflow
$3,545K
Net decrease in
cash, cash...
-$24,060K
(93.64%↑ Y/Y)
Canceled cashflow
$14,724K
Maturities of short-term
investments
$106,260K
(-15.66%↓ Y/Y)
Net loss
-$21,972K
(61.70%↑ Y/Y)
Deferred revenue
-$10,118K
Accretion of discounts on
investments, net
$2,886K
(-69.39%↓ Y/Y)
Prepaid expenses and
other current assets
$1,612K
(53.67%↑ Y/Y)
Accounts payable
-$342K
(34.73%↑ Y/Y)
Operating lease
right-of-use assets and...
$38K
(245.45%↑ Y/Y)
something is missing
-$3,545K
Net cash used in
investing activities
-$38,784K
(88.55%↑ Y/Y)
Canceled cashflow
$106,260K
Purchases of short-term
investments
$144,842K
(-68.78%↓ Y/Y)
Purchases of property and
equipment
$202K
(-76.07%↓ Y/Y)
Buy us a coffee